This HTML5 document contains 162 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00590/identifier/chemspider/
dctermshttp://purl.org/dc/terms/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00590/identifier/chebi/
n14http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00590/identifier/wikipedia/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00590/identifier/pharmgkb/
n12http://www.drugs.com/
n7http://bio2rdf.org/drugbank:
n25http://linked.opendata.cz/resource/drugbank/drug/DB00590/identifier/kegg-compound/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00590/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n11http://www.rxlist.com/cgi/generic/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00590/identifier/pubchem-substance/
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00590/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n30http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00590/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00590
rdf:type
n3:Drug
n3:description
Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic &alpha;<sub>1</sub>-adrenergic receptors. It may be used to mild to moderate hypertension and in the management of symptomatic benign prostatic hyperplasia (BPH). &alpha;<sub>1</sub>-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland.
n3:dosage
n22:271B5160-363D-11E5-9242-09173F13E4C5 n22:271B5161-363D-11E5-9242-09173F13E4C5 n22:271B515C-363D-11E5-9242-09173F13E4C5 n22:271B515D-363D-11E5-9242-09173F13E4C5 n22:271B515E-363D-11E5-9242-09173F13E4C5 n22:271B515F-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12461301
n3:group
approved
n3:halfLife
22 hours
n3:indication
For treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH.
n3:manufacturer
n5:271B5141-363D-11E5-9242-09173F13E4C5 n5:271B513F-363D-11E5-9242-09173F13E4C5 n5:271B5140-363D-11E5-9242-09173F13E4C5 n5:271B513D-363D-11E5-9242-09173F13E4C5 n5:271B513E-363D-11E5-9242-09173F13E4C5 n5:271B513B-363D-11E5-9242-09173F13E4C5 n5:271B513C-363D-11E5-9242-09173F13E4C5 n5:271B5139-363D-11E5-9242-09173F13E4C5 n5:271B513A-363D-11E5-9242-09173F13E4C5 n5:271B5137-363D-11E5-9242-09173F13E4C5 n5:271B5138-363D-11E5-9242-09173F13E4C5 n5:271B5135-363D-11E5-9242-09173F13E4C5 n5:271B5136-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00590 n8:DB00590
dcterms:title
Doxazosin
adms:identifier
n18:46506825 n19:Doxazosin n23:PA449407 n24:3157 n25:C06970 n26:0378-4021-01 n27:DB00590 n28:4708 n29:3045
n3:mechanismOfAction
Doxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
n3:packager
n5:271B5127-363D-11E5-9242-09173F13E4C5 n5:271B5128-363D-11E5-9242-09173F13E4C5 n5:271B5125-363D-11E5-9242-09173F13E4C5 n5:271B5126-363D-11E5-9242-09173F13E4C5 n5:271B512B-363D-11E5-9242-09173F13E4C5 n5:271B512C-363D-11E5-9242-09173F13E4C5 n5:271B5129-363D-11E5-9242-09173F13E4C5 n5:271B512A-363D-11E5-9242-09173F13E4C5 n5:271B512F-363D-11E5-9242-09173F13E4C5 n5:271B5130-363D-11E5-9242-09173F13E4C5 n5:271B512D-363D-11E5-9242-09173F13E4C5 n5:271B512E-363D-11E5-9242-09173F13E4C5 n5:271B5133-363D-11E5-9242-09173F13E4C5 n5:271B5134-363D-11E5-9242-09173F13E4C5 n5:271B5131-363D-11E5-9242-09173F13E4C5 n5:271B5132-363D-11E5-9242-09173F13E4C5 n5:271B5120-363D-11E5-9242-09173F13E4C5 n5:271B5123-363D-11E5-9242-09173F13E4C5 n5:271B5124-363D-11E5-9242-09173F13E4C5 n5:271B5121-363D-11E5-9242-09173F13E4C5 n5:271B5122-363D-11E5-9242-09173F13E4C5 n5:271B510D-363D-11E5-9242-09173F13E4C5 n5:271B510E-363D-11E5-9242-09173F13E4C5 n5:271B510B-363D-11E5-9242-09173F13E4C5 n5:271B510C-363D-11E5-9242-09173F13E4C5 n5:271B5111-363D-11E5-9242-09173F13E4C5 n5:271B5112-363D-11E5-9242-09173F13E4C5 n5:271B510F-363D-11E5-9242-09173F13E4C5 n5:271B5110-363D-11E5-9242-09173F13E4C5 n5:271B5115-363D-11E5-9242-09173F13E4C5 n5:271B5116-363D-11E5-9242-09173F13E4C5 n5:271B5113-363D-11E5-9242-09173F13E4C5 n5:271B5114-363D-11E5-9242-09173F13E4C5 n5:271B5119-363D-11E5-9242-09173F13E4C5 n5:271B511A-363D-11E5-9242-09173F13E4C5 n5:271B5117-363D-11E5-9242-09173F13E4C5 n5:271B5118-363D-11E5-9242-09173F13E4C5 n5:271B5109-363D-11E5-9242-09173F13E4C5 n5:271B510A-363D-11E5-9242-09173F13E4C5 n5:271B511D-363D-11E5-9242-09173F13E4C5 n5:271B511E-363D-11E5-9242-09173F13E4C5 n5:271B511B-363D-11E5-9242-09173F13E4C5 n5:271B511C-363D-11E5-9242-09173F13E4C5 n5:271B511F-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
On average only 4.8% of the dose was excreted as unchanged drug in the feces and only a trace of the total radioactivity in the urine was attributed to unchanged drug.
n3:synonym
Doxazosine Doxazosin Doxazosina Doxazosin mesylate Doxazosin mesilate 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin Doxazosinum 1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
n3:toxicity
Symptoms of overdose include hypotension. Oral LD<sub>50</sub> is greater than 1000 mg/kg in mice and rats.
n13:hasAHFSCode
n14:24-20-00
n3:foodInteraction
Avoid natural licorice. Avoid alcohol. Take without regard to meals.
n3:proteinBinding
98%
n3:synthesisReference
K. S. Keshava Murthy, Gamini Weeratunga, Tianhao Zhou, Bhaskar Reddy Guntoori, "Process for the manufacture of intermediates suitable to make doxazosin, terazosin, prazosin, tiodazosin and related antihypertensive medicines." U.S. Patent US5919931, issued September, 1986.
n15:hasConcept
n16:M0026251
foaf:page
n11:doxazo.htm n12:doxazosin.html n30:car1069.shtml
n3:IUPAC-Name
n4:271B5166-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B516C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B516B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5168-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5169-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B516A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B517C-363D-11E5-9242-09173F13E4C5 n4:271B5164-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5162-363D-11E5-9242-09173F13E4C5 n4:271B5165-363D-11E5-9242-09173F13E4C5 n4:271B517E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5163-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n20:C02CA04
n3:H-Bond-Acceptor-Count
n4:271B5172-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5173-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B516D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B516E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5170-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B516F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5171-363D-11E5-9242-09173F13E4C5
n3:absorption
65%
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
74191-85-8
n3:category
n3:containedIn
n9:271B5145-363D-11E5-9242-09173F13E4C5 n9:271B5146-363D-11E5-9242-09173F13E4C5 n9:271B5143-363D-11E5-9242-09173F13E4C5 n9:271B5144-363D-11E5-9242-09173F13E4C5 n9:271B5147-363D-11E5-9242-09173F13E4C5 n9:271B5148-363D-11E5-9242-09173F13E4C5 n9:271B514C-363D-11E5-9242-09173F13E4C5 n9:271B514D-363D-11E5-9242-09173F13E4C5 n9:271B514A-363D-11E5-9242-09173F13E4C5 n9:271B514B-363D-11E5-9242-09173F13E4C5 n9:271B5150-363D-11E5-9242-09173F13E4C5 n9:271B5151-363D-11E5-9242-09173F13E4C5 n9:271B514E-363D-11E5-9242-09173F13E4C5 n9:271B514F-363D-11E5-9242-09173F13E4C5 n9:271B5154-363D-11E5-9242-09173F13E4C5 n9:271B5155-363D-11E5-9242-09173F13E4C5 n9:271B5152-363D-11E5-9242-09173F13E4C5 n9:271B5153-363D-11E5-9242-09173F13E4C5 n9:271B5158-363D-11E5-9242-09173F13E4C5 n9:271B5159-363D-11E5-9242-09173F13E4C5 n9:271B5156-363D-11E5-9242-09173F13E4C5 n9:271B5157-363D-11E5-9242-09173F13E4C5 n9:271B5149-363D-11E5-9242-09173F13E4C5 n9:271B515A-363D-11E5-9242-09173F13E4C5 n9:271B515B-363D-11E5-9242-09173F13E4C5 n9:271B5142-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5178-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B517A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B517B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B517D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5177-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5176-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5179-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5167-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5174-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5175-363D-11E5-9242-09173F13E4C5